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In a hospital and health center–based study in
Nicaragua, fluid intake during the 24 hours before being
seen by a clinician was statistically associated with
decreased risk for hospitalization of dengue fever patients.
Similar results were obtained for children <15 years of age
and older adolescents and adults in independent analyses. 
D
engue fever (DF) and dengue hemorrhagic
fever/dengue shock syndrome (DHF/DSS) are major
public health problems worldwide (1). In addition to caus-
ing considerable illness and death, dengue epidemics also
have a major economic impact, attributable primarily to
the cost of medical care, plus vector control programs and
lost productivity (2,3). DF and DHF/DSS are indistin-
guishable in the initial febrile phase, and few reliable clin-
ical prognostic indicators of DHF/DSS exist (4). Near the
time of defervescence, the plasma leakage syndrome of
DHF/DSS can develop suddenly and be fatal if not man-
aged properly. As a result, in areas relatively new to
dengue, such as Latin America where DF and DHF/DSS
have been spreading over the last 2 decades, high hospital-
ization rates for DF can occur because of the fear of dis-
charging a patient whose case may progress to DHF/DSS.
As DHF/DSS becomes hyperendemic, as in Southeast
Asia, and extensive experience is garnered in case man-
agement, most hospitalizations for dengue are due to frank
DHF/DSS. We conducted a study to assess the extent of
hospitalization attributable to dengue in Nicaragua and to
examine the role of factors such as prior fluid intake on the
risk for hospitalization.
The Study
Participating hospitals and health centers in urban cen-
ters of the Pacific region of Nicaragua included the
Hospital Escuela Oscar Danilo Rosales Argüello in León,
the pediatric reference Hospital Infantil Manuel de Jesus
Rivera in Managua, and four health centers in Managua,
which serve a combined population of 1.95 million people.
A cross-sectional study of 2,820 suspected dengue cases
was conducted from January 1 to December 31, 1999.
Enrollment criteria consisted of acute febrile illness
accompanied by two or more of the following symptoms
of DF: fever, severe headache, retroorbital pain, myalgias,
arthralgias, and rash (4,5). A standardized questionnaire
was used to collect demographic and clinical information,
including ingestion of fluids in the 24 hours before first
being seen by a clinician, as reported by the patient or par-
ent. Of the 1,312 patients who tested positive for DENV
infection, the mean age was 15.3 years (range 0–85), and
557 (42%) were male (Table 1). Venous blood was drawn
at the first visit, and convalescent-phase serum specimens
were obtained when possible (19% of patients). Clinical
evolution of the illness among hospitalized patients was
documented by chart review with standardized data-entry
forms. This study was approved by the Institutional
Review Boards of both University of California, Berkeley
(#99-4-38) and the Centro Nacional de Diagnóstico y
Referencia of the Nicaraguan Ministry of Health (#99-04).
Dengue virus (DENV) infection was identified in 1,312
patients by serologic methods (immunoglobulin M-capture
enzyme-linked immunosorbent assay [ELISA] or inhibi-
tion ELISA for total anti-DENV antibodies), virologic
means (virus isolation, reverse transcriptase-polymerase
chain reaction), or both (5). DENV2, DENV4, and
DENV3 accounted for 79%, 17%, and 5% of the typed
viruses, respectively. Dengue fever was divided into clas-
sic DF and DF with hemorrhagic manifestations
(DFHem); severe dengue was defined as DHF (World
Health Organization classification DHF grades I and II),
DSS (World Health Organization DHF grades III and IV)
(1), or an additional classification designated “dengue with
signs associated with shock” (DSAS). DSAS was desig-
nated when either hypotension for age or narrow pulse
pressure plus clinical signs of shock were present and seri-
al hematocrit and platelet counts failed to document throm-
bocytopenia and hemoconcentration, potentially attributa-
ble to fluid replacement therapy (5). The relationship
between hospitalization and fluid intake was assessed by
unconditional logistic regression. Because virtually every
patient with severe dengue was hospitalized, such risk fac-
tor analysis was not suitable for these patients as a separate
group. Thus, the analysis was restricted to DF and DFHem
patients. Univariate and multivariate analyses were per-
formed separately on children (<15 years of age) and older
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found to be significant in univariate analyses were includ-
ed in the initial multivariate models (Table 2). 
Although a much higher proportion of severe dengue
patients were hospitalized compared with DF and DFHem
patients, larger absolute numbers of hospitalizations were
due to classic DF and DFHem because many more cases of
DF/DFHem than of severe dengue occur (Table 1). Thus,
of all the laboratory-confirmed DENV-positive hospital-
ized patients, classic DF (23.5%) and DFHem (50.0%)
cases comprised three times as many as DHF, DSS, and
DSAS combined (23.6%). These profiles have been main-
tained from year to year, with 28% and 20% of hospital-
ized cases due to classic DF and 51% and 58% due to
DFHem in 1998 and 2000, respectively (5). Furthermore,
the mean duration of hospitalization was similar for
patients with DF and those with severe dengue (Table 1). 
Conclusions
Among children with DF or DFHem, ingestion of fluid
in the 24 hours before being seen by a clinician was found
to be protective against hospitalization after adjusting for
distance from health facility, date of symptom onset, and
thrombocytopenia (odds ratio [OR]=0.74 per each addi-
tional glass consumed, 95% confidence intervals [CI] 0.66
to 0.83, p<0.01) (Table 2). Similar results were obtained
for older adolescents and adults after adjusting for date of
symptom onset and thrombocytopenia, with an OR of 0.71
(95% CI 0.59 to 0.85, p<0.01). In analyses with a statisti-
cal model that did not assume a linear relationship between
number of glasses ingested and hospitalization, additional
benefit was noted for each glass up to five, after which the
incremental benefit remained constant. Thus, in a model
that compared the fluid intake of five glasses or less than
five glasses with ingestion of more than five glasses, the
adjusted OR for hospitalization was 0.19 (95% CI 0.09 to
0.39, p<0.01) among DF and DFHem cases in children and
0.20 (95% CI 0.07 to 0.57, p<0.01) in those >15 years of
age (Table 2). We also performed the analysis with all dis-
ease states, including severe dengue cases, and the results
were virtually identical to those obtained with only
DF/DFHem cases (data not shown).
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Table 1. Characteristics of all hospitalized and unhospitalized dengue patients  






Mean (sd) or  




Mean (sd) or 




Mean (sd) or 
% of group 
Demographic data             
Age (y)  478  9.4 (8.9)  834  18.7 (15.5)  1,312  15.3 (14.2) 
Male  229  47.8%  328  39.2%  557  42.3% 
Distance (km) to health facility  464  10.0 (25.0)  831  2.7 (6.1)  1,295  5.3 (16.1) 
Disease classification
a             
Classic DF
  113  23.5%  706  84.4%  819  62.1% 
DFHem  240  50.0%  129  15.4%  369  28.0% 
DHF  67  14.0%  0  0%  67  5.1% 
DSS  16  3.3%  1  0.1%  17  1.3% 
DSAS  30  6.3%  0  0%  30  2.3% 
No classification  14  2.9%  1  0.1%  15  1.1% 
Duration of hospitalization (days)
b             
Classic DF  52  5.7 (1.7)         
DFHem  95  5.1 (1.7)         
DHF  56  6.1
c (1.5)         
DSS  15  6.9
c,d (1.9)         
DSAS  28  6.1
c (1.8)         
No classification  11  6.2 (1.9)         
Clinical data at presentation             
No. of glasses of fluid ingested 














Thrombocytopenia  289  60.2%  58  6.9%  347  26.4% 
Anorexia  239  50.9%  422  53.3 %  661  52.4% 
Stomach pain  271  58.4%  404  51.5%  675  54.4% 
Days since onset of symptoms  476  5.5 (5.6)  826  5.2 (5.7)  1,302  5.3 (5.7) 
aDF, dengue fever; DFHem, DF with hemorrhagic manifestations; DHF, dengue hemorrhagic fever; DSS, dengue shock syndrome; DSAS, dengue with signs associated 
with shock. 
bInformation on the duration of hospitalization was available from 52 (46%) of hospitalized classic DF patients; 95 (40%) of hospitalized DFHem patients; 56 (84%) of 
hospitalized DHF patients; 15 (94%) of hospitalized DSS patients; and 28 (93%) of hospitalized DSAS patients. Outliers (>12 days) were removed before analysis. 
cThe mean duration of hospitalization was significantly longer for DHF cases, DSS cases, and DSAS cases as compared with duration for DFHem cases (p<0.05 for each, 
Student t test). 
dThe mean duration of hospitalization was significantly longer for DSS cases compared with duration for classic DF cases (p<0.05, Student t test). 
eThe average glass contains approximately 8 oz. The most common liquid ingested was water (70%),
followed by fruit juice (42%), lemonade (27%), milk
(25%), coffee (14%), oral dehydration serum (6%), and tea
(2%). The mean number of glasses ingested by nonhospi-
talized DF/DFHem case-patients was 5.2, whereas the
mean number glasses ingested by hospitalized DF/DFHem
patients was 2.8, similar to the mean of 2.9 glasses ingest-
ed by hospitalized severe patients (DHF/DSS/DSAS).
These findings suggest that maintaining hydration may
lead to reduced hospitalizations of patients with
DF/DFHem. Other independent risk factors for hospital-
ization included in the final multivariate model were
increasing distance from the healthcare facility, later date
of symptom onset, and the presence of thrombocytopenia.
The risk conferred by later date of symptom onset reflects
increased awareness of dengue by medical staff as the
annual epidemic intensified. Because thrombocytopenia is
an indication for hospitalization (especially for pediatric
dengue patients), its emergence as a risk factor is not sur-
prising.
Because inpatient medical care of DF and DFHem
patients can contribute significantly to the economic
impact of dengue, we sought to define outpatient measures
that could decrease DF hospitalization rates. Dengue
patients are likely to be susceptible to dehydration because
of high fever and concomitant anorexia. While oral rehy-
dration therapy is listed as standard outpatient management
for DHF (1), little discussion exists on the use of such ther-
apy for DF and DFHem cases (4), and no published studies
have examined the effect of fluid intake at home. Our
results show that this simple measure may have a signifi-
cant protective effect against hospitalization and potential-
ly on the severity of DF/DFHem, although causality cannot
be confirmed because of the observational nature of this
study. To definitively demonstrate this effect, this question
must be investigated by prospective intervention studies.
However, our data do suggest that promoting a high fluid
intake at home could help reduce the need for hospitaliza-
tion and thus attenuate economic impact of dengue in
countries experiencing epidemics of dengue fever.
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Table 2. Crude and adjusted odds ratios and 95% confidence intervals for factors potentially associated with hospitalization for classic 
dengue fever or dengue fever with hemorrhagic manifestations 
  Children (<15 years of age)























Fluid intake during 24-h 
period before presentation 
587      405     
For each additional glass    0.68 (0.62 to 0.75)  0.74 (0.66 to 0.83)    0.67 (0.5 to 0.79)  0.71 (0.59 to 0.85) 
>5 glasses    0.14 (0.08 to 0.25)  0.19 (0.09 to 0.39)
e    0.16 (0.06 to 0.43)  0.20 (0.07 to 0.57)
g 
Age  719    —
h  464    — 
For each additional year    0.93 (0.8 to 0.97)      0.98 (0.96 to 1.00)   
Sex  718      464     
Male  395  1.43 (1.06 to 1.94)    291  1.27 (0.74 to 2.17)   
Female  323      173     
Distance from healthcare 
facility 
701      460     
For each additional 5 km    2.13 (1.68 to 2.69)  1.46 (1.12 to 1.91)    1.16 (0.92 to 1.46)  — 
Date of onset of symptoms  709      455     
For each additional 
month 
  1.26 (1.16 to 1.37)  1.51 (1.26 to 1.81)    1.87 (1.53 to 2.29)  2.08 (1.53 to 2.83) 
Days between onset of 




    457     
For each additional day    1.04 (1.0 to 1.07)  —    0.98 (0.93 to 1.03)  — 
Thrombocytopenia  499      227     
Yes  189  6.5 (4.25 to 9.96)  6.16 (3.57 to 10.64)  33  3.31 (1.53 to 7.15)  3.62 (1.24 to 10.52) 
No  310      194     
Stomach pain  681      439     
Yes  370  0.94 (0.69 to 1.28)  —  216  1.50 (0.89 to 2.56)  — 
No  311      223     
aThe age distribution of children <15 years of age was 7.2 (SD 3.9) with a range from 0 to 14 years and that of older adolescents and adults was 30.6 (SD 13.9) with a 
range of 15 to 85 years. 
bThe numbers differ based on completeness of information for each variable. 
cOR, odds ratios; CI, 95% confidence intervals. 
dAdjusted for glasses of liquid consumed (continuous variable), distance from healthcare facility, date of onset of symptoms, and thrombocytopenia. 
eThe adjusted OR and 95% CI for glasses of liquid consumed (dichotomous variable) were obtained from a separate model that adjusted for the same factors as footnote d. 
fAdjusted for glasses of liquid consumed (continuous variable), date of onset of symptoms, and thrombocytopenia. 
gThe adjusted OR and 95% CI for glasses of liquid consumed (dichotomous variable) were obtained from a separate model that adjusted for the same factors as footnote f. 
h Dash
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